



Confederation of Indian Industry

## 1<sup>st</sup> National Biotechnology Conclave 2017

***Strengthening the Biotech Ecosystem in India***

22 December 2017: Hotel Le Meridien, New Delhi

### Program Grid

22 December 2017		Page
0830-1000	Registration & Networking Tea/Coffee	
1000-1100	Inaugural Session	1
1100-1200	Panel Discussion I: Way forward for the Vaccine industry	2
1200-1300	Panel discussion II: Striking Gold with the Biosimilar opportunity	3
1300-1400	Networking Lunch	
1400-1500	Panel Discussion III: Biotech Start up Eco System in India	4-5
1500-1600	Panel Discussion IV: Ease of doing business in Biotech Sector	6
1600-1615	Networking Tea/Coffee	
1615-1715	Panel discussion V: Role of Govt, Academia and Private Players in driving India's biotech sector	7



Confederation of Indian Industry

## 1<sup>st</sup> National Biotechnology Conclave 2017

***Strengthening the Biotech Ecosystem in India***

22 December 2017: Hotel Le Meridien, New Delhi

### INAUGURAL SESSION

**22 December 2017; 1000 – 1100 HRS**

1000-1015 Hrs	Welcome Address	<b>Dr Arun Chandavarkar</b> Chairman, CII National Committee on Biotechnology CEO and Joint Managing Director Biocon Ltd.
1015-1025 Hrs	Special Address	<b>Dr Renu Swarup</b> Managing Director, BIRAC & Senior Adviser, Department of Biotechnology
1025-1040 Hrs	Keynote Address	<b>Dr K VijayRaghavan</b> Secretary Department of Biotechnology
1040-1045 Hrs	Inaugural Address by the Chief Guest	<b>Honorable Dr Harsh Vardhan*</b> Honorable Minister for Science and Technology
<b>Release of Vaccine paper</b>		
1055-1100 Hrs	Concluding Remarks	<b>Mr. R.K. Suri</b> Chief Executive Officer Panacea Biotec Ltd.

**0830-1000 Hrs: Registration & Networking Tea/Coffee**



Confederation of Indian Industry

## 1<sup>st</sup> National Biotechnology Conclave 2017

***Strengthening the Biotech Ecosystem in India***

22 December 2017: Hotel Le Meridien, New Delhi

### PANEL DISCUSSION 1

**22 December 2017; 1100 – 1200 HRS**

#### Panel discussion: Way forward for the Vaccine industry

*The Indian vaccine industry has achieved great heights with 70% of the total global volume being manufactured in India. Ambiguities in regulatory norms, however, still limit its true potential and require refinement. These regulations need to be addressed appropriately looking at the country's needs and not through mimicking the global ones. CII's vaccine Subcommittee headed by Dr Rajesh Jain submitted three such proposals to the Health Ministry last winter. This panel will deliberate the way forward and discuss the impact of those proposals on the 'ease of doing' vaccine business.*

1100-1105 Hrs	Opening Remarks by the Moderator	<b>Mr. R.K. Suri</b> Chief Executive Officer Panacea Biotec Ltd.
1105-1110 Hrs	Special Address	<b>Dr. V. G. Somani</b> Joint Drug Controller General of India Central Drugs Standard Control Organization  <b>Dr Arun Bhardwaj*</b> Director CDL Kasauli
1110-1150 Hrs	Remarks by the Panelists	<b>Dr V P Kamboj</b> Chairman Review Committee on Genetic Manipulation (RCGM)  <b>Ms Mahima Datla</b> Managing Director Biological E Limited  <b>Dr Krishna Ella</b> Chairman and Managing Director Bharat Biotech International Limited  <b>Dr Suresh Jadhav</b> Executive Director Serum Institute of India Limited  <b>Dr Anand Kumar</b> Managing Director Indian Immunologicals
1150-1200 Hrs	Closing Remarks by the Moderator	



Confederation of Indian Industry

# 1<sup>st</sup> National Biotechnology Conclave 2017

## ***Strengthening the Biotech Ecosystem in India***

22 December 2017: Hotel Le Meridien, New Delhi

### PANEL DISCUSSION 2

**22 December 2017; 1200 – 1300 HRS**

#### **Panel discussions: Striking Gold with the Biosimilar opportunity**

*The biosimilars opportunity is expected to grow to a whopping \$240 billion by 2030. In India it is expected to increase from \$186 million in 2016 to \$1.1 billion in 2020, according to industry estimates. As affordable alternatives, they offer the promise of expanding healthcare access to critical care biologic treatments. India has taken a lead here with Indian industry actively engaging in biosimilars with more than 10 of the 20 companies investing in biosimilars and more than 60 molecules approved in India. Indian companies are doing it all - going on their own, investing in India and strategic global locations, partnering globally for Rest of World (RoW) and regulated markets. The below panel will discuss next ten year strategy to accomplish India's dominant position in regulated and RoW markets.*

1200-1205 Hrs	Opening Remarks by the Moderator	<b>Ms Pushpa Vijayraghavan</b> Director Sathguru Management Consultants
1205-1210 Hrs	Special Address	<b>Dr Arun Chandavarkar</b> Chairman, CII National Committee on Biotechnology & CEO and Joint Managing Director Biocon Ltd.
1210-1245 Hrs	Remarks by the Panelists	<b>Mr Jaspreet Singh</b> Vice President_ Quality, INTAS PHARMACEUTICALS Ltd. (Biopharma Division)  <b>Dr. Gopal Dasika</b> Head - Biologics Development Center Hospira Healthcare India Pvt. Ltd. (a Pfizer company)  <b>Dr. Kiran Marthak</b> Director - Head Global Clinical Development Lambda Therapeutic Research Limited
1245-1300 Hrs	Closing Remarks by the Moderator	
<b>1300-1400 Hrs</b>	<b>Networking Lunch</b>	



Confederation of Indian Industry

## 1<sup>st</sup> National Biotechnology Conclave 2017

### *Strengthening the Biotech Ecosystem in India*

22 December 2017: Hotel Le Meridien, New Delhi

#### PANEL DISCUSSION 3

22 December 2017; 1400 – 1500 HRS

#### Panel discussion: Biotech Start up Eco System in India

*The Indian Biotech start-up ecosystem is booming with over \$ 2.8 billion investment in five years from 2012 to 2016. There are however, several challenges that need to be addressed to embark on a higher and faster growth trajectory. This panel will address the surge of biotech innovation in India with convergence of the bioentrepreneurship, early stage funding, incubation infrastructure and the conducive policy environment providing opportunity for national and global bioentrepreneurs and entities to pursue innovation in India. The enormously changing mindset of the Indian enterprises to pursue cutting edge innovation in life sciences has triggered not just the PE investors but the Government itself to commit significant funding for supporting seed to growth stage. The session also proposes to discuss the strategies for building capital to fund the scale up stages of the biotech start-up ecosystem in India.*

1400-1405 Hrs	Opening Remarks by the Moderator	<b>Mr Vishal Gandhi</b> Founder and Executive Director Bio-RX Venture Advisor Pvt Ltd
1405-1420 Hrs	Special Address	<b>Dr Shirshendu Mukherjee</b> Mission Director PMU (DBT- BIRAC-BMGF-Wellcome Trust)
1420-1450 Hrs	Remarks by the Panelists	<p><b>Mr N Venkat</b> Co-founder &amp; CEO Vyome Biosciences</p> <p><b>Dr. Taslimarif Saiyed</b> CEO and Director Centre for Cellular and Molecular Platforms</p> <p><b>Mr Vikas Sharma</b> Chairman &amp; Founder H2Life Foundation</p> <p><b>Mr. Sandeep Singh</b> Partner Eight Roads Ventures Pvt Ltd.</p> <p><b>Mr Sunil Thakur</b> Director &amp; Chief Operating Officer Quadria Capitol</p>
1450-1500 Hrs	Closing Remarks by the Moderator	



Confederation of Indian Industry

## 1<sup>st</sup> National Biotechnology Conclave 2017

***Strengthening the Biotech Ecosystem in India***

22 December 2017: Hotel Le Meridien, New Delhi

### PANEL DISCUSSION 4

**22 December 2017; 1500 – 1600 HRS**

#### Panel discussion: Ease of doing business in Biotech Sector

*Biotechnology sector has a very prominent role to play in the flagship “Make in India” programme of the Government of India. There is no doubt that India has a huge potential to become a leading bio-tech hub but there is also a pressing need for simplifying regulatory processes and forming growth conducive policies for the potential to realize. The session would discuss the issues faced by companies in operating in India and suggest both short term and long term recommendations for running commercially successful Life Science business in India.*

1500-1505 Hrs	Opening Remarks by the Moderator	<b>Dr Prabuddha Kundu</b> Co-founder & Executive Director Premas Biotech Pvt. Ltd.
1505-1515 Hrs	Special Address	<b>Dr Garima Gupta*</b> Scientist 'D' Department of Biotechnology
1515-1545 Hrs	Remarks by the Panelists	<b>Mr Mahesh Bhalgat</b> Chief Operating Officer Sanofi  <b>Dr Deepa Tikku</b> Partner K&S Partners  <b>Mr Anil Sood</b> Senior Vice President, Commercial Vaccine Manufacturing MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.  <b>Mr. Arjun Surya</b> President & CSO Curadev Pharma Pvt. Ltd
1545-1550 Hrs	<b><i>Release of Bio Diversity Act whitepaper in the session</i></b>	
1550-1600 Hrs	Closing Remarks by the Moderator	
<b>1600-1615 Hrs</b>	<b>Networking Tea/Coffee</b>	



Confederation of Indian Industry

## 1<sup>st</sup> National Biotechnology Conclave 2017

***Strengthening the Biotech Ecosystem in India***

22 December 2017: Hotel Le Meridien, New Delhi

### PANEL DISCUSSION 5

**22 December 2017; 1615 – 1715 HRS**

#### **Panel discussion: Role of Govt, Academia and Private Players in driving India's biotech sector**

*There is little doubt that academic and biotech researchers can accomplish far more together than either can do alone. Radical new ways of working and a culture of external collaboration are key elements in turning around pharmaceutical R&D productivity and bringing new and cost-effective medicines to patients faster. Many biotech and pharma companies are working to dramatically improve their ability to harness knowledge and capability residing both within and beyond their organizational boundaries for bettering their R&D efforts. Given the increasing pressures for cost-cutting in the developed markets, global R&D expenditure in Lifesciences has seen a migration towards Asia, including India building collaborations and partnerships that tap into India's talent pool, local innovation, as well as the vast patient population, much of which is "treatment-naïve". On the other hand, Indian companies are also entering cross-border alliances and importing skills, finance and knowledge while upgrading their ability to conduct R&D. Both these trends are expected to be bolstered by the government's efforts to improve infrastructure, funding, and intellectual property (IP) protection which needs to be more clearly defined and readily enforceable.*

*This session will focus upon how we can put our current resources to best use and ease the formation of alliances for increasing R&D productivity supported by some case studies of successful vehicles of collaboration such as the Prime Minister's Fellowship Scheme for Doctoral Research.*

1615-1620 Hrs	Opening Remarks by the Moderator	<b>Dr Anil Koul</b> Director IMTECH (CSIR), Chandigarh
1620-1630 Hrs	Special Address	<b>Dr Jitendra Kumar</b> Director and Head Bangalore Bioinnovation Centre (BBC) Bangalore, Karnataka
1630-1710 Hrs	Remarks by the Panelists	<b>Dr Deepak Pental</b> Professor Dept of Genetics, University of Delhi  <b>Dr Satyanarayana V. Nandury</b> Chief Scientist & Head, Business Development & Technology Outreach Division Indian Institute of Chemical Technology  <b>Dr Aman Gupta</b> Deputy General Manager Regulatory Affairs Cadila Pharmaceuticals Ltd  <b>Dr. Pawan Kumar Gupta</b> Stempeutics Research Pvt. Ltd.
1710-1715 Hrs	Closing Remarks by the Moderator	